Endogenex Names Stacey Pugh as New CEO

Clinical-stage medical device company Endogenex has appointed Stacey Pugh as its new CEO. She will lead the firm as it expands clinical initiatives to evaluate the novel ReCET procedure to treat type 2 diabetes.
 
“We are thrilled to have Stacey join the Endogenex team,” James Eadie MD, Endogenex Board Member and Managing Director, Santé, told the press. “Stacy is a proven leader with extensive experience in running global clinical and commercial stage medical device organizations. She is an expert in clinical affairs and market access strategy. Stacey has the track record of having led a high-growth business at scale while transforming clinical care, and now her skills will enable Endogenex to realize the significant potential of this technology.”
 
Pugh was previously chief commercial officer at Butterfly Network and president of Medtronic’s neurovascular business. She spent the first half of her career leading clinical and medical affairs at Medtronic, Covidien, and Kinetic Concepts.
 
“I am excited to join the talented Endogenex team at this important stage,” said Pugh. “Endogenex is uniquely positioned to make a significant impact in the treatment of Type 2 Diabetes with a proprietary treatment targeted at the underlying causes of the disease. I look forward to partnering with our investigators and advisors as we further expand our clinical evidence and advance our technology to serve millions of people worldwide who suffer from this chronic condition.” 
 
The ReCET endoscopic, outpatient procedure targets underlying cellular abnormalities in the duodenum that contribute to development and progression of type 2 diabetes. ReCET uses highly controlled, non-thermal pulsed electric fields to initiate the body’s natural regenerative process to restore proper cellular signaling from the duodenum and improve metabolic function.